Taurine: 1 g Does Nothing, and the Research Dose Starts at 3 g

Walk any supplement aisle and pick up a bottle of taurine. The number on the front is almost always 500 mg or 1,000 mg. Occasionally a stand-alone bottle will hit 2 g per serving. The serving size is almost always one or two capsules, and the marketing implicitly treats that number as the working dose. It is not. 500 mg is close to a rounding error against what a healthy adult synthesizes endogenously each day from cysteine and methionine. 1 g is below the threshold of most trials that have found a cardiovascular, endurance, or metabolic signal. The modern research literature that has run controlled trials with taurine has almost universally used 3 to 6 g per day, and in some indications up to 10 g.

The historical energy-drink use of the word "taurine" is not helping the label-literacy conversation. A standard 250 mL energy drink lists 1,000 mg of taurine on the back, and consumers who reach for a stand-alone taurine capsule frequently pattern-match to that same 1,000 mg as the effective dose. The energy-drink formula is a marketing shape carrying caffeine-adjacent branding. It is not a taurine trial. Reaching for a 500 mg capsule once a day and expecting the outcomes the modern research has documented is a label-literacy error, and it is the pattern the industry has quietly leaned into.

This is the same underdosing signature that runs through the proprietary blends problem, the electrolyte-powder sodium underdose, and the NAC 600 mg floor. The number on the front of the bottle is doing work the trial dose should be doing.

What Taurine Actually Does

Taurine is a sulfur-containing amino acid, but not one of the twenty proteinogenic amino acids — it is not incorporated into protein. Instead, taurine floats as a free amino acid in high concentrations in the heart, skeletal muscle, brain, retina, and leukocytes, where it participates in three broad functional groups.

Osmoregulation. Taurine is one of the largest free intracellular osmolytes, particularly in cardiomyocytes and skeletal muscle. It participates in cell-volume regulation under osmotic stress, which is part of why the tissue concentrations are so high (10 to 50 mM in some tissues) — the volume-regulatory role requires a large substrate pool.

Calcium handling and membrane stabilization. Taurine modulates calcium flux across the sarcoplasmic reticulum in cardiac and skeletal muscle. This is part of the mechanism proposed for the cardiovascular effects (blood pressure, arrhythmia risk in some populations, left-ventricular function in heart failure) and part of the mechanism proposed for the exercise-performance effects (fatigue resistance in endurance efforts).

Bile-acid conjugation. Taurine conjugates with cholic acid to form taurocholic acid, one of the primary bile acids. This is a house-keeping metabolic role that runs continuously in healthy adults and has clinical relevance in populations with cholestatic disease or with genetic disorders of taurine synthesis.

There is also an aging-biology conversation around taurine — a 2023 Science paper and follow-on work documented declining plasma taurine with age across mammals and reversal of some aging biomarkers with taurine supplementation in animal models. This is early literature. It is not a call to load taurine as an anti-aging protocol, but it is worth noting as one of the reasons research doses have been climbing in recent trials.

Endogenous taurine synthesis in a healthy adult runs at roughly 50 to 125 mg per day from cysteine and methionine substrate. Dietary intake in an omnivorous diet from shellfish, dark meat, and organ meats runs 40 to 400 mg per day depending on the frequency of those foods. A strict vegan intake runs close to zero because plants do not contain taurine. Endogenous synthesis is not fully sufficient to maintain plasma taurine in all populations, and a 500 mg supplemental dose is meaningful additive intake against the baseline. What it is not is the pharmacologic-effect dose used in the trial literature.

What the Research Actually Doses

The controlled-trial literature on taurine spans several use cases. None of the modern ones show a signal at 500 mg or 1 g.

• Cardiovascular / heart-failure adjunct: 3 to 6 g/day. Trials in patients with chronic heart failure have used 3 g/day (some have gone to 6 g) and have documented improvements in left-ventricular ejection fraction, exercise tolerance, and NYHA functional class. These are meaningful clinical endpoints in a population with a real disease, and the dose is well above the retail-capsule shape.
• Blood pressure in hypertensive adults: 1.6 to 6 g/day. Meta-analyses of taurine and blood pressure have found modest but consistent reductions in both systolic and diastolic pressure at doses starting around 1.6 g/day, with a stronger signal at 3 g/day and above. A 500 mg capsule does not clear the trial threshold.
• Endurance-exercise performance: 1 to 6 g/day, single-dose 1 to 3 g pre-exercise. The endurance literature is mixed and the single-dose acute-effect trials are the ones that have most consistently shown a signal. Most use a 1 to 3 g dose taken 60 to 120 minutes before the effort. Chronic loading trials at 1 to 6 g/day have shown improved time-to-exhaustion in some designs.
• Insulin sensitivity and metabolic-syndrome markers: 3 g/day. Trials in patients with metabolic syndrome, prediabetes, or type 2 diabetes have used 3 g/day for 8 to 16 weeks and shown modest improvements in insulin sensitivity, HbA1c, and lipid markers. Below the 3 g threshold the signal is weak.
• Aging biomarkers (early literature, mostly animal): human trials still in progress but at doses of 3 to 6 g/day where they have been reported.
• Bipolar disorder adjunctive treatment: up to 10 g/day in the small trials that have explored the psychiatric indications. This is at the upper end of what has been tested in a human trial and is not a general-consumer dose.

The convergence point across the modern indications is 3 g per day as the floor of the therapeutic range and 6 g per day as the upper end for most general-consumer indications. A single 500 mg or 1 g capsule once daily is not the trial dose. It is the marketing shape of a one-capsule serving multiplied by the assumption that consumers will not do the arithmetic.

Why the Energy-Drink Label Is Not a Dose Reference

A standard 250 mL energy drink lists 1,000 mg of taurine alongside 80 mg of caffeine, B vitamins, and sugars. The formula was designed decades ago in the pre-modern-trial era, and the 1,000 mg number reflects a mixture of marketing shape (round number, close to the endogenous daily flux), regulatory palatability (well below any dose that would have safety-review implications), and cost-management (taurine is not free). It was never a taurine-effect dose. It was a functional-drink ingredient chosen for the branding association.

Reaching for a stand-alone taurine capsule and matching the energy-drink 1,000 mg number is a natural consumer heuristic and one of the most common ways the underdosing pattern replicates. The taurine capsule at 1 g does what the energy drink's taurine does, which is essentially nothing measurable on the individual endpoint. The rest of the energy drink's effect is caffeine, sugar, and the psychological ritual of the can.

Timing and Split-Dose Considerations

Taurine is well absorbed orally with a plasma half-life of roughly 1 to 2 hours. A single 3 g dose loads plasma to a peak at 60 to 120 minutes and returns to baseline within about 6 hours. Steady-state chronic dosing pushes tissue concentrations up more slowly (weeks) because tissue equilibration lags the plasma-level curve.

The practical protocol most trials use for chronic indications:

• Two split doses of 1.5 g each, one at morning and one at evening, delivering a total of 3 g/day. This is the standard protocol for the cardiovascular, blood-pressure, and metabolic trials.
• Single 3 g dose in the morning if compliance is a barrier — the tissue-level effect is not meaningfully different across a chronic loading window.
• Single 1 to 3 g pre-exercise for acute endurance-performance use. Taken 60 to 120 minutes before the effort with water; no food required.

Taurine is well tolerated across the trial range. Above 6 g/day some individuals report mild GI discomfort, and the safety-review data on chronic doses above 10 g/day is thinner. The 3 g/day protocol is the well-supported starting point for a healthy adult reaching for taurine on a cardiovascular, metabolic, or endurance indication.

Taurine Is Not the Same Conversation as NAC or Glycine

Taurine, NAC, and glycine all show up in the same corner of the supplement aisle and get treated as interchangeable amino-acid-esque support products. They are not.

• NAC feeds cysteine into glutathione synthesis. The functional role is antioxidant support, liver load, and mood in specific indications.
• Glycine is a proteinogenic amino acid that participates in glutathione synthesis (paired with cysteine via NAC in the GlyNAC protocol), collagen synthesis, and inhibitory neurotransmission.
• Taurine does none of those things directly. Its roles are osmoregulation, calcium handling, and bile-acid conjugation. The trial evidence base sits on cardiovascular, metabolic, and endurance endpoints.

Buying a "cell health complex" or an "amino acid stack" that lumps taurine, NAC, and glycine together at 200 to 500 mg each is the same underdosing pattern the proprietary blends piece walks through. Each of the three has its own trial-dose range, and no blend that fits all three into a single capsule delivers a trial dose of any of them.

Who Should Be Cautious

Taurine has a strong safety record across the trial doses discussed here, but a few populations warrant a conversation with a clinician before starting a 3 g/day protocol.

• People on lithium. Taurine has been reported to potentiate lithium's effect in animal models; the clinical relevance is not fully worked out and psychiatric medication choices sit with the prescriber.
• People with impaired sulfation or with a diagnosed disorder of sulfur amino-acid metabolism. Taurine is a downstream metabolite of the cysteine-methionine pool and cases are individual.
• Pregnant and lactating individuals. Taurine is important in fetal development and infant nutrition, and endogenous production runs high in this window. Supplemental doses at the 3 g/day pharmacologic range sit outside the standard pregnancy-supplementation conversation and should be a physician decision.
• People on antihypertensive medications. The blood-pressure-lowering effect of a 3 g/day protocol is real and can compound with prescription antihypertensives.

Reading a Taurine Label

Three things to check on the bottle.

1. Milligrams per capsule and total per serving. A "1,000 mg taurine" bottle where the serving size is one capsule delivers 1 g. A "1,000 mg taurine per serving" bottle where the serving size is two capsules delivers 500 mg per capsule. And a bottle where the front reads "high-potency taurine complex, 2 g" and the serving size is four capsules delivers 500 mg per capsule and 2 g per serving — which means hitting 3 g/day requires six capsules a day. Do the arithmetic on the label. The front-of-bottle number rarely tells you the per-capsule dose.

2. Form and free-amino-acid claim. The label should read "taurine" or "L-taurine" or "2-aminoethanesulfonic acid." Taurine is achiral and does not have a D-form to worry about, so "L-taurine" is a marketing embellishment rather than a form claim. A bottle that lists taurine as part of a "cardiovascular support blend" or a "cell hydration complex" alongside four other ingredients is doing the proprietary-blend underdose.

3. Nothing else in the capsule that shouldn't be there. A single-ingredient taurine capsule with a light excipient package (rice flour, cellulose, magnesium stearate) is what the trial literature uses. A branded "endurance stack" with taurine among six other ingredients is not.

Sourcing note: fermentation-derived taurine and synthetic taurine are pharmacologically equivalent. The "vegan taurine" positioning some brands use is a supply-chain claim, not a bioavailability claim.

The Bottom Line

500 mg to 1 g of taurine is the historical energy-drink shape and the retail-capsule serving size, and the modern trial literature on the outcomes people actually reach for taurine on — cardiovascular support, blood pressure, endurance performance, insulin sensitivity, aging biomarkers — runs at 3 to 6 g per day. A single 500 mg or 1 g capsule once daily is not the trial dose. It is the size of the historical energy-drink allotment.

The label-literacy rule for taurine is the same one that runs through the underdosed corners of the supplement aisle: check the milligrams per serving against the trial range, buy plain single-ingredient taurine rather than a blend, split the dose across the day (or single-dose it pre-exercise for acute use), and treat 3 g/day as the floor of the useful range, not the ceiling.

The 1 g number on the front of the bottle is what the energy-drink category asked for in 1985. The trial dose is what the modern research has documented since. Those are not the same number, and the shopper who wants what the research describes has to reach for the second one.